Single-Atom Iridium Nanozyme-Based Persistent Luminescence Nanoparticles for Multimodal Imaging-Guided Combination Tumor Therapy

Yang Li; Shu-Qi Wu; Fang Nan; Wei Deng; Kaixuan Li; Nur Jarhen; Yitong Zhou; Qianli Ma; Yuanyuan Qu; Chaoxiang Chen; Yujing Ren; Xue-Bo Yin

doi:10.1002/adhm.202402544

Single-Atom Iridium Nanozyme-Based Persistent Luminescence Nanoparticles for Multimodal Imaging-Guided Combination Tumor Therapy

Adv Healthc Mater. 2024 Sep 29:e2402544. doi: 10.1002/adhm.202402544. Online ahead of print.

Authors

Yang Li¹, Shu-Qi Wu¹, Fang Nan¹, Wei Deng¹, Kaixuan Li¹, Nur Jarhen¹, Yitong Zhou¹, Qianli Ma¹, Yuanyuan Qu¹, Chaoxiang Chen², Yujing Ren^{1

3}, Xue-Bo Yin⁴

Affiliations

¹ School of Life Sciences, Key Laboratory of Space Bioscience & Biotechnology, Northwestern Polytechnical University, Xi'an, 710072, China.
² Department of Biological Engineering, College of Food and Biological Engineering, Jimei University, Xiamen, Fujian, 361021, China.
³ Chongqing Innovation Center, Northwestern Polytechnical University, Chongqing, 401135, China.
⁴ Institute for Frontier Medical Technology, College of Chemistry and Chemical Engineering, Shanghai University of Engineering Science, Shanghai, 201620, China.

PMID: 39344246
DOI: 10.1002/adhm.202402544

Abstract

Persistent luminescence nanoparticles (PLNPs) can achieve autofluorescence-free afterglow imaging, while near-infrared (NIR) emission realizes deep tissue imaging. Nanozymes integrate the merits of nanomaterials and enzyme-mimicking activities with simple preparation. Here PLNPs are prepared of Zn_1.2Ga_1.6Ge_0.2O₄:Cr_0.0075 with NIR emission at 700 nm. The PLNPs are then incubated with IrCl₃ solution, and the nanoparticles are collected and annealed at 750 °C to obtain iridium@PLNPs. Iridium is observed on the PLNPs at the atomic level as a single-atom nanozyme with peroxidase-like catalytic activity, photothermal conversion, and computed tomography (CT) contrast capability. After coating with exosome membrane (EM), the Ir@PLNPs@EM composite exhibits long-lasting NIR luminescence, peroxidase-like catalytic activity, photothermal conversion, and CT contrast capability, with the targeting capability and biocompatibility from EM. Thus, NIR afterglow/photothermal/CT trimodal imaging-guided photothermal-chemodynamic combination therapy is realized as validated with the in vitro and in vivo inhibition of tumor growth, while toxicity and side effects are avoided as drug-free treatment. This work offers a promising avenue for advanced single-atom nanozyme@PLNPs to promote the development of nanozymes and PLNPs for clinical applications.

Keywords: chemodynamic therapy; persistent luminescence nanoparticles; photothermal therapy; single‐atom nanozyme; trimodal imaging.

Abstract

Grants and funding